Hims & Hers Health is back in the spotlight after a class action lawsuit and related regulatory complaints over data privacy and billing practices, raising fresh questions for investors about risk, governance, and long term business quality. The legal headlines come as the stock has shown mixed momentum, up 5.11% over the last week but down 13.32% across three months, with a 1-year total shareholder return of negative 49.62% following a three-year gain of more than 3x. Against a last close of $29.42, the most followed valuation narrative on Simply Wall St points to a fair value of $171.19, implying the stock is 83% undervalued, though the company's price-to-sales ratio of 2.7x sits above the US Healthcare industry at 1.3x and peers at 2.2x. The story faces real pressure if legal actions escalate or if international expansion slows and weighs on already negative net income.
Hims Hers Health IncClass action lawsuit and regulatory complaints over data privacy and billing practices raise legal/governance risk for Hims & Hers.
